The Hypereosinophilic Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypereosinophilic Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Hypereosinophilic Syndrome by seven companies/universities/institutes. The top development phase for Hypereosinophilic Syndrome is phase ii with four drugs in that stage. The Hypereosinophilic Syndrome pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypereosinophilic Syndrome pipeline products market are: GSK, Shanghai Novamab Biopharmaceuticals and Nexeos Bio.
The key targets in the Hypereosinophilic Syndrome pipeline products market include Interleukin 5, Interleukin 5 Receptor, and Interleukin 5 Receptor Subunit Alpha.
The key mechanisms of action in the Hypereosinophilic Syndrome pipeline product include Interleukin 5 Inhibitor with two drugs in Phase III. The Hypereosinophilic Syndrome pipeline products include six routes of administration with the top ROA being Subcutaneous and four key molecule types in the Hypereosinophilic Syndrome pipeline products market including Monoclonal Antibody, and Small Molecule.
Hypereosinophilic Syndrome overview
Hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.
For a complete picture of Hypereosinophilic Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
